Ciara Murray

Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018.

C. Quinn, G. Gullo, L. Flanagan, 2019, Archives of pathology & laboratory medicine.

Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma

C. Quinn, G. Gullo, L. Flanagan, 2019, Virchows Archiv.

Composite Blastoid Variant of Mantle Cell Lymphoma and Classical Hodgkin Lymphoma

C. Grant, R. Flavin, Jan Walker, 2017, International journal of surgical pathology.

Toward a quantitative method for estimating tumour-stroma ratio in breast cancer using polarized light microscopy.

A. Vitkin, S. Nofech-Mozes, Blake Jones, 2021, Biomedical optics express.

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases

I. Ellis, E. Provenzano, S. Pinder, 2021, British Journal of Cancer.

Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? ASCO/College of American Pathologists Guidelines 2007, 2013, and 2018.

C. Quinn, G. Gullo, L. Flanagan, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer

I. Ellis, E. Provenzano, S. Pinder, 2021, Modern Pathology.

Evaluation of an enhanced pathological examination protocol for sentinel lymph nodes from patients with breast carcinoma

C. Ó'Riain, B. Dunne, A. Maguire, 2020, Journal of Clinical Pathology.

Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma

E. Atenafu, T. May, S. Piedimonte, 2024, Gynecologic Oncology.